Cargando…

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus

OBJECTIVE: We explored the potential of neurofilament light chain (NfL) in serum and cerebrospinal fluid as a biomarker for neurodestruction in status epilepticus. METHODS: In a retrospective analysis, we measured NfL in serum and cerebrospinal fluid samples of patients with status epilepticus using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margraf, Nils G., Dargvainiene, Justina, Theel, Emily, Leypoldt, Frank, Lieb, Wolfgang, Franke, Andre, Berger, Klaus, Kuhle, Jens, Kuhlenbaeumer, Gregor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10025237/ https://www.ncbi.nlm.nih.gov/pubmed/36624182 http://dx.doi.org/10.1007/s00415-022-11547-4

Ejemplares similares

NfL and pNfH are increased in Friedreich’s ataxia
por: Hayer, Stefanie Nicole, et al.
Publicado: (2020)

Combined use of CSF NfL and CSF TDP‐43 improves diagnostic performance in ALS
por: Kasai, Takashi, et al.
Publicado: (2019)

The Role of Serum Levels of Neurofilament Light (NfL) Chain as a Biomarker in Friedreich Ataxia
por: Frempong, Bernice, et al.
Publicado: (2021)

Plasma Neurofilament Light (NfL) in Patients Affected by Niemann–Pick Type C Disease (NPCD)
por: Dardis, Andrea, et al.
Publicado: (2021)

Neurofilament light chain levels predict encephalopathy and outcome in community‐acquired pneumonia
por: Chung, Ha‐Yeun, et al.
Publicado: (2022)

Generalized Polyspike Pattern in EEG Due to Aseptic Meningoencephalitis
por: Hobert, Markus A., et al.
Publicado: (2023)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

CSF neurofilament light chain reflects corticospinal tract degeneration in ALS
por: Menke, Ricarda A L, et al.
Publicado: (2015)

Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels
por: Camara-Lemarroy, Carlos, et al.
Publicado: (2022)

Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease
por: Steinacker, Petra, et al.
Publicado: (2016)

NEUROFILAMENT LIGHT CHAIN (NFL) AND GENERAL COGNITIVE ABILITY IN ADULTS APPROACHING MIDLIFE
por: Reynolds, Chandra, et al.
Publicado: (2022)

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015)

Neurofilament Light Chain (NfL) in Blood—A Biomarker Predicting Unfavourable Outcome in the Acute Phase and Improvement in the Late Phase after Stroke
por: Pekny, Milos, et al.
Publicado: (2021)

Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1)
por: Nicoletti, Tommaso F., et al.
Publicado: (2022)

Editorial: The Impact of Neurofilament Light Chain (NFL) Quantification in Serum and Cerebrospinal Fluid in Neurodegenerative Diseases
por: Zanella, Isabella, et al.
Publicado: (2022)

CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community‐based sample of 70‐year‐olds
por: Dittrich, Anna, et al.
Publicado: (2022)

Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis
por: Yalachkov, Yavor, et al.
Publicado: (2022)

Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model
por: Dreger, Marie, et al.
Publicado: (2021)

Ratio and index of Neurofilament light chain indicate its origin in Guillain‐Barré Syndrome
por: Körtvelyessy, Peter, et al.
Publicado: (2020)

Blood neurofilament light chain at the doorstep of clinical application
por: Leppert, David, et al.
Publicado: (2019)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS
por: Lokhande, Hrishikesh, et al.
Publicado: (2022)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters
por: Hermesdorf, Marco, et al.
Publicado: (2022)

The neurofilament derived-peptide NFL-TBS.40-63 enters in-vitro in human neural stem cells and increases their differentiation
por: Barreau, Kristell, et al.
Publicado: (2018)

Neurofilament light chain predicts future dementia risk in cerebral small vessel disease
por: Egle, Marco, et al.
Publicado: (2021)

Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2020)

Salivary S100 calcium-binding protein beta (S100B) and neurofilament light (NfL) after acute exposure to repeated head impacts in collegiate water polo players
por: Monroe, Derek C., et al.
Publicado: (2022)

CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis
por: Pawlitzki, Marc, et al.
Publicado: (2019)

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Schindler, Patrick, et al.
Publicado: (2021)

The Use of Biologics in NFL Athletes: An Expert Consensus of NFL Team Physicians
por: Murray, Iain R., et al.
Publicado: (2023)

Is CSF neurofilament light chain measurement relevant for MS?
por: Matsui, Makoto
Publicado: (2020)

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
por: Gisslén, Magnus, et al.
Publicado: (2015)

Antibodies to neurofilament light as potential biomarkers in multiple sclerosis
por: Puentes, Fabiola, et al.
Publicado: (2021)

Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum
por: Herrera-Rivero, Marisol, et al.
Publicado: (2023)

Increased CSF NFL in Non-demented Parkinson’s Disease Subjects Reflects Early White Matter Damage
por: Papuć, Ewa, et al.
Publicado: (2020)

A Method to Combine Neurofilament Light Measurements From Blood Serum and Plasma in Clinical and Population-Based Studies
por: Rübsamen, Nicole, et al.
Publicado: (2022)

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
por: Hansson, Oskar, et al.
Publicado: (2017)

Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria
por: Kern, Daniela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_18iogn8n32j5aien7f1bfgvm7t